1 |
Lucas DT and Szweda LI (1998) Cardiac reperfusion injury: aging, lipid peroxidation, and mitochondrial dysfunction. Proc Natl Acad Sci U S A 95, 510-514
DOI
|
2 |
Murphy E and Steenbergen C (2008) Mechanisms underlying acute protection from cardiac ischemia-reperfusion injury. Physiol Rev 88, 581-609
DOI
|
3 |
Brenner C and Moulin M (2012) Physiological roles of the permeability transition pore. Circ Res 111, 1237-1247
DOI
|
4 |
Kwong JQ and Molkentin JD (2015) Physiological and pathological roles of the mitochondrial permeability transition pore in the heart. Cell Metab 21, 206-214
DOI
|
5 |
Huss JM and Kelly DP (2005) Mitochondrial energy metabolism in heart failure: a question of balance. J Clin Invest 115, 547-555
DOI
|
6 |
Towbin JA and Bowles NE (2002) The failing heart. Nature 415, 227-233
DOI
|
7 |
Wagner JA, Weisman HF, Snowman AM, Reynolds IJ, Weisfeldt ML and Snyder SH (1989) Alterations in calcium antagonist receptors and sodium-calcium exchange in cardiomyopathic hamster tissues. Circ Res 65, 205-214
DOI
|
8 |
Li Y, Huang TT, Carlson EJ et al (1995) Dilated cardiomyopathy and neonatal lethality in mutant mice lacking manganese superoxide dismutase. Nat Genet 11, 376-381
DOI
|
9 |
Shipp JC, Opie LH and Challoner D (1961) Fatty acid and glucose metabolism in the perfused heart. Nature 189, 1018-1019
DOI
|
10 |
Bersin RM, Wolfe C, Kwasman M et al (1994) Improved hemodynamic function and mechanical efficiency in congestive heart failure with sodium dichloroacetate. J Am Coll Cardiol 23, 1617-1624
DOI
|
11 |
Lewis JF, DaCosta M, Wargowich T and Stacpoole P (1998) Effects of dichloroacetate in patients with congestive heart failure. Clin Cardiol 21, 888-892
DOI
|
12 |
Arakawa K, Kudo T, Ikawa M et al (2010) Abnormal myocardial energy-production state in mitochondrial cardiomyopathy and acute response to L-arginine infusion. C-11 acetate kinetics revealed by positron emission tomography. Circ J 74, 2702-2711
DOI
|
13 |
Lebrecht D, Geist A, Ketelsen UP, Haberstroh J, Setzer B and Walker UA (2007) Dexrazoxane prevents doxorubicin-induced long-term cardiotoxicity and protects myocardial mitochondria from genetic and functional lesions in rats. Br J Pharmacol 151, 771-778
DOI
|
14 |
Konorev EA, Kennedy MC and Kalyanaraman B (1999) Cell-permeable superoxide dismutase and glutathione peroxidase mimetics afford superior protection against doxorubicin-induced cardiotoxicity: the role of reactive oxygen and nitrogen intermediates. Arch Biochem Biophys 368, 421-428
DOI
|
15 |
Fisher PW, Salloum F, Das A, Hyder H and Kukreja RC (2005) Phosphodiesterase-5 inhibition with sildenafil attenuates cardiomyocyte apoptosis and left ventricular dysfunction in a chronic model of doxorubicin cardiotoxicity. Circulation 111, 1601-1610
DOI
|
16 |
Abozguia K, Elliott P, McKenna W et al (2010) Metabolic modulator perhexiline corrects energy deficiency and improves exercise capacity in symptomatic hypertrophic cardiomyopathy. Circulation 122, 1562-1569
DOI
|
17 |
Lebrecht D, Setzer B, Ketelsen UP, Haberstroh J and Walker UA (2003) Time-dependent and tissue-specific accumulation of mtDNA and respiratory chain defects in chronic doxorubicin cardiomyopathy. Circulation 108, 2423-2429
DOI
|
18 |
Lionetti V, Linke A, Chandler MP et al (2005) Carnitine palmitoyl transferase-I inhibition prevents ventricular remodeling and delays decompensation in pacing-induced heart failure. Cardiovasc Res 66, 454-461
DOI
|
19 |
van der Vijgh WJ, van Velzen D, van der Poort JS et al (1988) Morphometric study of myocardial changes during doxorubicin-induced cardiomyopathy in mice. Eur J Cancer Clin Oncol 24, 1603-1608
DOI
|
20 |
Shenasa H, Calderone A, Vermeulen M et al (1990) Chronic doxorubicin induced cardiomyopathy in rabbits: mechanical, intracellular action potential, and beta adrenergic characteristics of the failing myocardium. Cardiovasc Res 24, 591-604
DOI
|
21 |
Kerr DS (2010) Treatment of mitochondrial electron transport chain disorders: a review of clinical trials over the past decade. Mol Genet Metab 99, 246-255
DOI
|
22 |
Gurlek A, Tutar E, Akcil E et al (2000) The effects of L-carnitine treatment on left ventricular function and erythrocyte superoxide dismutase activity in patients with ischemic cardiomyopathy. Eur J Heart Fail 2, 189-193
DOI
|
23 |
Singh RB, Niaz MA, Rastogi V and Rastogi SS (1998) Coenzyme Q in cardiovascular disease. J Assoc Physicians India 46, 299-306
|
24 |
Buyse GM, Van der Mieren G, Erb M et al (2009) Long-term blinded placebo-controlled study of SNT-MC17/idebenone in the dystrophin deficient mdx mouse: cardiac protection and improved exercise performance. Eur Heart J 30, 116-124
DOI
|
25 |
Zhang M, Wei J, Shan H et al (2013) Calreticulin-STAT3 signaling pathway modulates mitochondrial function in a rat model of furazolidone-induced dilated cardiomyopathy. PLoS One 8, e66779
DOI
|
26 |
Lagedrost SJ, Sutton MS, Cohen MS et al (2011) Idebenone in Friedreich ataxia cardiomyopathy-results from a 6-month phase III study (IONIA). Am Heart J 161, 639-645 e631
DOI
|
27 |
Rizos I (2000) Three-year survival of patients with heart failure caused by dilated cardiomyopathy and L-carnitine administration. Am Heart J 139, S120-123
DOI
|
28 |
Hajjar RJ, Liao R, Young JB, Fuleihan F, Glass MG and Gwathmey JK (1993) Pathophysiological and biochemical characterisation of an avian model of dilated cardiomyopathy: comparison to findings in human dilated cardiomyopathy. Cardiovasc Res 27, 2212-2221
DOI
|
29 |
Armstrong PW, Stopps TP, Ford SE and de Bold AJ (1986) Rapid ventricular pacing in the dog: pathophysiologic studies of heart failure. Circulation 74, 1075-1084
DOI
|
30 |
Spinale FG, Hendrick DA, Crawford FA, Smith AC, Hamada Y and Carabello BA (1990) Chronic supraventricular tachycardia causes ventricular dysfunction and subendocardial injury in swine. Am J Physiol 259, H218-229
|
31 |
Ide T, Tsutsui H, Kinugawa S et al (1999) Mitochondrial electron transport complex I is a potential source of oxygen free radicals in the failing myocardium. Circ Res 85, 357-363
DOI
|
32 |
Melov S, Coskun P, Patel M et al (1999) Mitochondrial disease in superoxide dismutase 2 mutant mice. Proc Natl Acad Sci U S A 96, 846-851
DOI
|
33 |
Lefrak EA, Pitha J, Rosenheim S and Gottlieb JA (1973) A clinicopathologic analysis of adriamycin cardiotoxicity. Cancer 32, 302-314
DOI
|
34 |
Vicart P, Caron A, Guicheney P et al (1998) A missense mutation in the alphaB-crystallin chaperone gene causes a desmin-related myopathy. Nat Genet 20, 92-95
DOI
|
35 |
Gilladoga AC, Manuel C, Tan CT, Wollner N, Sternberg SS and Murphy ML (1976) The cardiotoxicity of adriamycin and daunomycin in children. Cancer 37, 1070-1078
DOI
|
36 |
Takemura G and Fujiwara H (2007) Doxorubicin-induced cardiomyopathy from the cardiotoxic mechanisms to management. Prog Cardiovasc Dis 49, 330-352
DOI
|
37 |
Sawyer DB (2013) Anthracyclines and heart failure. N Engl J Med 368, 1154-1156
DOI
|
38 |
Wang X, Osinska H, Dorn GW 2nd et al (2001) Mouse model of desmin-related cardiomyopathy. Circulation 103, 2402-2407
DOI
|
39 |
Maloyan A, Sanbe A, Osinska H et al (2005) Mitochondrial dysfunction and apoptosis underlie the pathogenic process in alpha-B-crystallin desmin-related cardiomyopathy. Circulation 112, 3451-3461
DOI
|
40 |
Badorff C, Lee GH, Lamphear BJ et al (1999) Enteroviral protease 2A cleaves dystrophin: evidence of cytoskeletal disruption in an acquired cardiomyopathy. Nat Med 5, 320-326
DOI
|
41 |
Feng J, Yan J, Buzin CH, Towbin JA and Sommer SS (2002) Mutations in the dystrophin gene are associated with sporadic dilated cardiomyopathy. Mol Genet Metab 77, 119-126
DOI
|
42 |
Vatta M, Stetson SJ, Perez-Verdia A et al (2002) Molecular remodelling of dystrophin in patients with end-stage cardiomyopathies and reversal in patients on assistance-device therapy. Lancet 359, 936-941
DOI
|
43 |
Paulin D, Huet A, Khanamyrian L and Xue Z (2004) Desminopathies in muscle disease. J Pathol 204, 418-427
DOI
|
44 |
Khairallah M, Khairallah R, Young ME, Dyck JR, Petrof BJ and Des Rosiers C (2007) Metabolic and signaling alterations in dystrophin-deficient hearts precede overt cardiomyopathy. J Mol Cell Cardiol 43, 119-129
DOI
|
45 |
Nakayama H, Chen X, Baines CP et al (2007) Ca2+- and mitochondrial-dependent cardiomyocyte necrosis as a primary mediator of heart failure. J Clin Invest 117, 2431-2444
DOI
|
46 |
Engel AG (1999) Myofibrillar myopathy. Ann Neurol 46, 681-683
DOI
|
47 |
Gray MW, Burger G and Lang BF (1999) Mitochondrial evolution. Science 283, 1476-1481
DOI
|
48 |
Fosslien E (2003) Review: Mitochondrial medicine--cardiomyopathy caused by defective oxidative phosphorylation. Ann Clin Lab Sci 33, 371-395
|
49 |
Wang J, Wilhelmsson H, Graff C et al (1999) Dilated cardiomyopathy and atrioventricular conduction blocks induced by heart-specific inactivation of mitochondrial DNA gene expression. Nat Genet 21, 133-137
DOI
|
50 |
Li H, Wang J, Wilhelmsson H et al (2000) Genetic modification of survival in tissue-specific knockout mice with mitochondrial cardiomyopathy. Proc Natl Acad Sci U S A 97, 3467-3472
DOI
|
51 |
Wisneski JA, Gertz EW, Neese RA and Mayr M (1987) Myocardial metabolism of free fatty acids. Studies with 14C-labeled substrates in humans. J Clin Invest 79, 359-366
DOI
|
52 |
Stanley WC and Chandler MP (2002) Energy metabolism in the normal and failing heart: potential for therapeutic interventions. Heart Fail Rev 7, 115-130
DOI
|
53 |
Graham BH, Waymire KG, Cottrell B, Trounce IA, MacGregor GR and Wallace DC (1997) A mouse model for mitochondrial myopathy and cardiomyopathy resulting from a deficiency in the heart/muscle isoform of the adenine nucleotide translocator. Nat Genet 16, 226-234
DOI
|
54 |
Stanley WC, Lopaschuk GD, Hall JL and McCormack JG (1997) Regulation of myocardial carbohydrate metabolism under normal and ischaemic conditions. Potential for pharmacological interventions. Cardiovasc Res 33, 243-257
DOI
|
55 |
Shirihai OS, Song M and Dorn GW 2nd (2015) How Mitochondrial Dynamism Orchestrates Mitophagy. Circ Res 116, 1835-1849
DOI
|
56 |
Ashrafian H, Docherty L, Leo V et al (2010) A mutation in the mitochondrial fission gene Dnm1l leads to cardiomyopathy. PLoS Genet 6, e1001000
DOI
|
57 |
Archer SL (2013) Mitochondrial dynamics--mitochondrial fission and fusion in human diseases. N Engl J Med 369, 2236-2251
DOI
|
58 |
Song M, Mihara K, Chen Y, Scorrano L and Dorn GW 2nd (2015) Mitochondrial fission and fusion factors reciprocally orchestrate mitophagic culling in mouse hearts and cultured fibroblasts. Cell Metab 21, 273-285
DOI
|
59 |
Chen Y and Dorn GW 2nd (2013) PINK1-phosphorylated mitofusin 2 is a Parkin receptor for culling damaged mitochondria. Science 340, 471-475
DOI
|
60 |
Song M, Chen Y, Gong G, Murphy E, Rabinovitch PS and Dorn GW 2nd (2014) Super-suppression of mitochondrial reactive oxygen species signaling impairs compensatory autophagy in primary mitophagic cardiomyopathy. Circ Res 115, 348-353
DOI
|
61 |
Chen Y, Liu Y and Dorn GW 2nd (2011) Mitochondrial fusion is essential for organelle function and cardiac homeostasis. Circ Res 109, 1327-1331
DOI
|
62 |
Kubli DA and Gustafsson AB (2012) Mitochondria and mitophagy: the yin and yang of cell death control. Circ Res 111, 1208-1221
DOI
|
63 |
Papanicolaou KN, Kikuchi R, Ngoh GA et al (2012) Mitofusins 1 and 2 are essential for postnatal metabolic remodeling in heart. Circ Res 111, 1012-1026
DOI
|
64 |
Chen L, Liu T, Tran A et al (2012) OPA1 mutation and late-onset cardiomyopathy: mitochondrial dysfunction and mtDNA instability. J Am Heart Assoc 1, e003012
DOI
|
65 |
Song M and Dorn GW 2nd (2015) Mitoconfusion: noncanonical functioning of dynamism factors in static mitochondria of the heart. Cell Metab 21, 195-205
DOI
|
66 |
Delbridge LM, Mellor KM, Taylor DJ and Gottlieb RA (2015) Myocardial autophagic energy stress responses--macroautophagy, mitophagy, and glycophagy. Am J Physiol Heart Circ Physiol 308, H1194-1204
DOI
|
67 |
Hoppel CL, Tandler B, Parland W, Turkaly JS and Albers LD (1982) Hamster cardiomyopathy. A defect in oxidative phosphorylation in the cardiac interfibrillar mitochondria. J Biol Chem 257, 1540-1548
|
68 |
D'Angelo DD, Sakata Y, Lorenz JN et al (1997) Transgenic Galphaq overexpression induces cardiac contractile failure in mice. Proc Natl Acad Sci U S A 94, 8121-8126
DOI
|
69 |
Sakata Y, Hoit BD, Liggett SB, Walsh RA and Dorn GW 2nd (1998) Decompensation of pressure-overload hypertrophy in G alpha q-overexpressing mice. Circulation 97, 1488-1495
DOI
|
70 |
Yussman MG, Toyokawa T, Odley A et al (2002) Mitochondrial death protein Nix is induced in cardiac hypertrophy and triggers apoptotic cardiomyopathy. Nat Med 8, 725-730
DOI
|
71 |
Shin G, Sugiyama M, Shoji T, Kagiyama A, Sato H and Ogura R (1989) Detection of mitochondrial membrane damages in myocardial ischemia with ESR spin labeling technique. J Mol Cell Cardiol 21, 1029-1036
DOI
|
72 |
Syed F, Odley A, Hahn HS et al (2004) Physiological growth synergizes with pathological genes in experimental cardiomyopathy. Circ Res 95, 1200-1206
DOI
|
73 |
Diwan A, Wansapura J, Syed FM, Matkovich SJ, Lorenz JN and Dorn GW 2nd (2008) Nix-mediated apoptosis links myocardial fibrosis, cardiac remodeling, and hypertrophy decompensation. Circulation 117, 396-404
DOI
|
74 |
Dorn GW 2nd (2010) Mitochondrial pruning by Nix and BNip3: an essential function for cardiac-expressed death factors. J Cardiovasc Transl Res 3, 374-383
DOI
|
75 |
Palmer JW, Tandler B and Hoppel CL (1985) Biochemical differences between subsarcolemmal and interfibrillar mitochondria from rat cardiac muscle: effects of procedural manipulations. Arch Biochem Biophys 236, 691-702
DOI
|
76 |
Lauritzen KH, Kleppa L, Aronsen JM et al (2015) Impaired dynamics and function of mitochondria caused by mtDNA toxicity leads to heart failure. Am J Physiol Heart Circ Physiol 309, H434-449
DOI
|
77 |
Sligh JE, Levy SE, Waymire KG et al (2000) Maternal germ-line transmission of mutant mtDNAs from embryonic stem cell-derived chimeric mice. Proc Natl Acad Sci U S A 97, 14461-14466
DOI
|
78 |
Baba A, Yoshikawa T, Fukuda Y et al (2004) Autoantibodies against M2-muscarinic acetylcholine receptors: new upstream targets in atrial fibrillation in patients with dilated cardiomyopathy. Eur Heart J 25, 1108-1115
DOI
|
79 |
Fu ML, Schulze W, Wallukat G, Hjalmarson A and Hoebeke J (1995) Functional epitope analysis of the second extracellular loop of the human heart muscarinic acetylcholine receptor. J Mol Cell Cardiol 27, 427-436
DOI
|
80 |
Fu LX, Magnusson Y, Bergh CH et al (1993) Localization of a functional autoimmune epitope on the muscarinic acetylcholine receptor-2 in patients with idiopathic dilated cardiomyopathy. J Clin Invest 91, 1964-1968
DOI
|
81 |
Zhang S, He Z, Wang J et al (2015) Mitochondrial Ultrastructural Alterations and Declined M2 Receptor Density Were Involved in Cardiac Dysfunction in Rats after Long Term Treatment with Autoantibodies against M2 Muscarinic Receptor. PLoS One 10, e0129563
DOI
|
82 |
Yoshizawa A, Nagai S, Baba Y et al (2012) Autoimmunity against M(2)muscarinic acetylcholine receptor induces myocarditis and leads to a dilated cardiomyopathy-like phenotype. Eur J Immunol 42, 1152-1163
DOI
|
83 |
Palmer JW, Tandler B and Hoppel CL (1977) Biochemical properties of subsarcolemmal and interfibrillar mitochondria isolated from rat cardiac muscle. J Biol Chem 252, 8731-8739
|
84 |
Cecchi F, Tomberli B and Olivotto I (2012) Clinical and molecular classification of cardiomyopathies. Glob Cardiol Sci Pract 2012, 4
DOI
|
85 |
Ozawa T (1994) Mitochondrial cardiomyopathy. Herz 19, 105-118, 125
|
86 |
Stanley WC and Hoppel CL (2000) Mitochondrial dysfunction in heart failure: potential for therapeutic interventions? Cardiovasc Res 45, 805-806
DOI
|
87 |
Lesnefsky EJ, Moghaddas S, Tandler B, Kerner J and Hoppel CL (2001) Mitochondrial dysfunction in cardiac disease: ischemia--reperfusion, aging, and heart failure. J Mol Cell Cardiol 33, 1065-1089
DOI
|
88 |
Recchia FA and Lionetti V (2007) Animal models of dilated cardiomyopathy for translational research. Vet Res Commun 31 Suppl 1, 35-41
DOI
|
89 |
Ikeda Y and Ross J Jr. (2000) Models of dilated cardiomyopathy in the mouse and the hamster. Curr Opin Cardiol 15, 197-201
DOI
|
90 |
Benjamin IJ and Schneider MD (2005) Learning from failure: congestive heart failure in the postgenomic age. J Clin Invest 115, 495-499
DOI
|
91 |
Wallace DC and Fan W (2010) Energetics, epigenetics, mitochondrial genetics. Mitochondrion 10, 12-31
DOI
|
92 |
Winnik S, Auwerx J, Sinclair DA and Matter CM (2015) Protective effects of sirtuins in cardiovascular diseases: from bench to bedside. Eur Heart J [Epub ahead of print]
|
93 |
Ryu D, Jo YS, Lo Sasso G et al (2014) A SIRT7-dependent acetylation switch of GABPbeta1 controls mitochondrial function. Cell Metab 20, 856-869
DOI
|
94 |
Roh JI, Cheong C, Sung YH et al (2014) Perturbation of NCOA6 leads to dilated cardiomyopathy. Cell Rep 8, 991-998
DOI
|
95 |
Walters AM, Porter GA Jr. and Brookes PS (2012) Mitochondria as a drug target in ischemic heart disease and cardiomyopathy. Circ Res 111, 1222-1236
DOI
|
96 |
Roger VL, Go AS, Lloyd-Jones DM et al (2012) Heart disease and stroke statistics--2012 update: a report from the American Heart Association. Circulation 125, e2-e220
DOI
|
97 |
Ambrosio G, Zweier JL, Duilio C et al (1993) Evidence that mitochondrial respiration is a source of potentially toxic oxygen free radicals in intact rabbit hearts subjected to ischemia and reflow. J Biol Chem 268, 18532-18541
|